Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFQ056 oral contraceptive drug-drug interaction study in healthy women
NL-OMON36456Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mavoglurant, ethinyl estradiol and avatrombopag in Fragile X syndrome (FXS) and Parkinson's disease (PD), sponsored by Novartis. Started Oct 2010; status: active, not recruiting.
02
Drugs
mavoglurantethinyl estradiolavatrombopag
03
Conditions
Fragile X syndrome (FXS)Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON36456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36456.